Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Conatus Data First Step In Liver Drug Pivotal Trial Design

This article was originally published in Scrip

Executive Summary

Conatus Pharmaceuticals Inc. reported mostly positive data from the first of two Phase II clinical trials that are meant to inform the design of pivotal trials for emricasan in the treatment of liver cirrhosis associated with alcoholism, non-alcoholic steatohepatitis (NASH) and the hepatitis C virus (HCV).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC029850

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel